BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//PYVOBJECT//NONSGML Version 1//EN
BEGIN:VTIMEZONE
TZID:Europe/Berlin
BEGIN:STANDARD
DTSTART:20001029T030000
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=10
TZNAME:CET
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
END:STANDARD
BEGIN:DAYLIGHT
DTSTART:20000326T020000
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=3
TZNAME:CEST
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
UID:20260520T210939Z - 88577@eupp247
DTSTART;TZID=Europe/Berlin:20230215T160000
DTEND;TZID=Europe/Berlin:20230215T170000
CREATED:20260520T210939Z
DESCRIPTION:<a href="https://academy.ant-neuro.com/event/atypical-neural-pr
 ocessing-in-22q11-2-deletion-syndrome-and-schizophrenia-towards-neuromarke
 rs-of-disease-progression-and-risks-10/register">Atypical neural processin
 g in 22q11.2 Deletion Syndrome and schizophrenia: Towards neuromarkers of 
 disease progression and risks</a>\nThis webinar has ended. You can watch t
 he recorded session here. Welcome to ANT Neuro Educational Webinar Series!
  22q11.2 Deletion Syndrome (22q11.2DS) is a multisystemic disorder charact
 erized by a wide range of clinical features\, ranging from life-threatenin
 g to less severe conditions. One-third of individuals with the deletion li
 ve with mild to moderate intellectual disability\; approximately 60% meet 
 criteria for at least one psychiatric condition. 22q11.2DS has become an i
 mportant model for several medical\, developmental\, and psychiatric disor
 ders. We have been particularly interested in understanding the risk for p
 sychosis in this population: Approximately 30% of the individuals with the
  deletion go on to develop schizophrenia. The characterization of cognitiv
 e and neural differences between those individuals who develop schizophren
 ia and those who do not\, despite being at genetic risk\, holds important 
 promise in what pertains to the clarification of paths to disease and to t
 he development of tools for early identification and intervention. The pre
 senter is Professor Sophie Molholm who is a Cognitive Neuroscientist at th
 e Albert Einstein College of Medicine\, with appointments in the departmen
 ts of Pediatrics\, Neuroscience and Psychiatry and Behavioral Sciences. Sh
 e uses multimodal brain imaging\, psychophysics\, and standardized cogniti
 ve and clinical assessments to probe the brain processes underlying percep
 tion and cognition in neurodevelopmental and neuropsychiatric conditions s
 uch as autism and schizophrenia as well as rare genetic disorders includin
 g 22q11.2 deletion syndrome and Rett syndrome. Her research is supported b
 y federal and foundation grants. In addition to running her lab\, she serv
 es as Co-Director of the NIH funded Rose F. Kennedy Intellectual and Devel
 opmental Research Center\, and an NIH supported training grant for postdoc
 toral fellows [...]
DTSTAMP:20260520T210939Z
LOCATION:Online
SUMMARY:Atypical neural processing in 22q11.2 Deletion Syndrome and schizop
 hrenia: Towards neuromarkers of disease progression and risks
X-ALT-DESC;FMTTYPE=text/html:<a href="https://academy.ant-neuro.com/event/a
 typical-neural-processing-in-22q11-2-deletion-syndrome-and-schizophrenia-t
 owards-neuromarkers-of-disease-progression-and-risks-10/register">Atypical
  neural processing in 22q11.2 Deletion Syndrome and schizophrenia: Towards
  neuromarkers of disease progression and risks</a>\nThis webinar has ended
 . You can watch the recorded session here. Welcome to ANT Neuro Educationa
 l Webinar Series! 22q11.2 Deletion Syndrome (22q11.2DS) is a multisystemic
  disorder characterized by a wide range of clinical features\, ranging fro
 m life-threatening to less severe conditions. One-third of individuals wit
 h the deletion live with mild to moderate intellectual disability\; approx
 imately 60% meet criteria for at least one psychiatric condition. 22q11.2D
 S has become an important model for several medical\, developmental\, and 
 psychiatric disorders. We have been particularly interested in understandi
 ng the risk for psychosis in this population: Approximately 30% of the ind
 ividuals with the deletion go on to develop schizophrenia. The characteriz
 ation of cognitive and neural differences between those individuals who de
 velop schizophrenia and those who do not\, despite being at genetic risk\,
  holds important promise in what pertains to the clarification of paths to
  disease and to the development of tools for early identification and inte
 rvention. The presenter is Professor Sophie Molholm who is a Cognitive Neu
 roscientist at the Albert Einstein College of Medicine\, with appointments
  in the departments of Pediatrics\, Neuroscience and Psychiatry and Behavi
 oral Sciences. She uses multimodal brain imaging\, psychophysics\, and sta
 ndardized cognitive and clinical assessments to probe the brain processes 
 underlying perception and cognition in neurodevelopmental and neuropsychia
 tric conditions such as autism and schizophrenia as well as rare genetic d
 isorders including 22q11.2 deletion syndrome and Rett syndrome. Her resear
 ch is supported by federal and foundation grants. In addition to running h
 er lab\, she serves as Co-Director of the NIH funded Rose F. Kennedy Intel
 lectual and Developmental Research Center\, and an NIH supported training 
 grant for postdoctoral fellows [...]
END:VEVENT
END:VCALENDAR